Besides the studies that have demonstrated utility in measuring both IL-6 and IL-8 individually in breast cancer and pancreatic cancer, the IL6/IL8 ratio is also an important factor that is currently being used to indicate disease outcomes. Here, IL6 is linked to familial pancreatic carcinoma.